Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Advanced fibrosis/cirrhosis is associated with reduced likelihood of SVR, including to DAA therapy
  • IL28B genotype is associated with interferon responsiveness and SVR to interferon-based therapy[Ge 2009; Tanaka 2009; Thomas 2009]
  • Higher IP-10 serum levels, higher BMI, and/or presence of insulin resistance are associated with treatment nonresponse in patients receiving interferon-based therapy[Lagging 2006; Diago 2006; Romero 2006]

    Action required

    Keywords: Hepatitis C-Prognosis, Hepatitis C-Treatment

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.